Allon Therapeutics has completed the enrolment of 300 patients in a Phase II/III pivotal trial to evaluate neuroprotective drug candidate Davunetide as a treatment for progressive supranuclear palsy, a rapidly progressing and fatal degenerative brain disease.

Davunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier human clinical and pre-clinical data suggested that Davunetide has shown significant impacts on memory, activities of daily living, and a biomarker of brain cell function and integrity.

The Phase II/III trial is being conducted under a special protocol assessment, which is based on efficacy demonstrated in patients with amnestic mild cognitive impairment and cognitive impairment associated with schizophrenia.

Allon president and CEO Gordon McCauley said the company expects to complete the treatment phase of the study and release data by the end of 2012.

"We expect that this pivotal study will provide the data sufficient for a regulatory submission for marketing approval," McCauley added.